---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-119701"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-11-15T23:59:59+00:00"
generated_at: "2026-05-30T00:09:43.331077+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata extends debt maturity to Jan 2026, terminates CMO, hires senior finance and regulatory leaders

## Summary
- Amended credit agreements with Innoviva; maturity moved to January 10, 2026.
- Terminated Chief Medical Officer Mina Pastagia, M.D., effective Nov 13, 2024; eligible for 12 months base salary severance.
- Hired David House as SVP Finance and Principal Financial Officer; hired Arwa Shurrab to lead regulatory strategy and operations.
- Preparing for two potential Phase 3 licensure-supporting trials in 2025 with expanded clinical and regulatory team.

## SEC filing metadata
- accession: 0001104659-24-119701
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/0001104659-24-119701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/tm2428608d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-119701
- JSON: https://secwatch.observer/filing/0001104659-24-119701.json
- Plain text: https://secwatch.observer/filing/0001104659-24-119701.txt

## Key facts
- Executive change
  Mina Pastagia was terminated as Chief Medical Officer at Armata Pharmaceuticals, Inc..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: On November 13, 2024 (the “Termination Date”), the Company terminated the employment of Mina Pastagia, M.D. (“Dr. Pastagia”), Chief Medical Officer of the Company, effective as of the close of business on the Termination Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465924119701/0001104659-24-119701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.